Phreesia, Inc. (NYSE:PHR – Get Free Report) General Counsel Allison C. Hoffman sold 1,238 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $22.86, for a total transaction of $28,300.68. Following the sale, the general counsel now directly owns 135,621 shares of the company’s stock, valued at $3,100,296.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Phreesia Trading Down 2.3 %
Shares of PHR opened at $22.62 on Friday. The firm’s 50 day moving average price is $24.40 and its 200 day moving average price is $21.26. The company has a quick ratio of 1.78, a current ratio of 1.78 and a debt-to-equity ratio of 0.02. Phreesia, Inc. has a twelve month low of $12.05 and a twelve month high of $34.98.
Phreesia (NYSE:PHR – Get Free Report) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.56) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.02. The firm had revenue of $95.00 million for the quarter, compared to analyst estimates of $93.52 million. Phreesia had a negative net margin of 38.42% and a negative return on equity of 53.33%. The company’s revenue for the quarter was up 24.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.72) earnings per share. As a group, equities research analysts forecast that Phreesia, Inc. will post -1.48 EPS for the current year.
Hedge Funds Weigh In On Phreesia
Wall Street Analyst Weigh In
A number of analysts have commented on PHR shares. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Friday, March 15th. Truist Financial started coverage on shares of Phreesia in a research note on Monday, February 26th. They set a “buy” rating and a $35.00 price objective for the company. Barclays started coverage on shares of Phreesia in a research note on Wednesday, January 3rd. They set an “overweight” rating and a $29.00 price objective for the company. DA Davidson reaffirmed a “neutral” rating and set a $32.00 price objective on shares of Phreesia in a research note on Friday, March 15th. Finally, Canaccord Genuity Group increased their price target on shares of Phreesia from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Phreesia currently has a consensus rating of “Moderate Buy” and an average price target of $31.62.
Check Out Our Latest Research Report on Phreesia
About Phreesia
Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.
See Also
- Five stocks we like better than Phreesia
- Following Congress Stock Trades
- Comprehensive PepsiCo Stock Analysis
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- Upcoming IPO Stock Lockup Period, Explained
- 3 Steel Stocks Could Soar on New China Tariffs
Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.